論文 - 下田 和哉
-
Vitamin D receptor-mediated skewed differentiation of macrophages initiates myelofibrosis and subsequent osteosclerosis. 査読あり
Kanako Wakahashi, Kentaro Minagawa, Yuko Kawano, Hiroki Kawano, Tomohide Suzuki, Shinichi Ishii, Akiko Sada, Noboru Asada, Mari Sato, Shigeaki Kato, Kotaro Shide, Kazuya Shimoda, Toshimitsu Matsui and Yoshio Katayama
Blood 133 ( 15 ) 1619 - 1629 2019年4月
-
大腸憩室多発領域に炎症が限局し、憩室性大腸炎との鑑別を要したアメーバ性大腸炎の1例
山本章二朗、小村杏奈、前村幸輔、後藤敏之、三池忠、田原良博、丸塚浩助、菊池郁夫、下田和哉
日本消化器内視鏡学会雑誌 61 ( 4 ) 381 - 386 2019年4月
記述言語：日本語 掲載種別：研究論文（学術雑誌）
-
Degradation of p47 by autophagy contributes to CADM1 overexpression in ATLL cells through the activation of NF-κB. 査読あり
Sarkar B., Nishikata I., Nakahata S., Ichikawa T., Shiraga T., Saha H., Fujii M., Tanaka Y., Shimoda K., Morishita K.
Scientific reports 9 ( 1 ) 3491 2019年3月
-
Efficacy and safety of sofosbuvir and ledipasvir in japanese patients aged 75 years or over with hepatitis C genotype 1. 査読あり
Ozono Y, Nagata K, Hasuike S, Iwakiri H, Nakamura K, Tsuchimochi M, Yamada Y, Takaishi Y, Sueta M, Miike T, Tahara Y, Yamamoto S, Shide K, Hidaka T, Kubuki Y, Kusumoto K, Ochiai T, Kato J, Komada N, Hirono S, Kuroki K, Shigehira M, Shimoda K
World Journal of Hepatology. 9 ( 36 ) 1340 - 1345 2018年12月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Kamiunten A., Shide K., Kameda T., Ito M., Sekine M., Kubuki Y., Hidaka T., Akizuki K., Tahira Y., Toyama T., Kawano N., Marutsuka K., Maeda K., Takeuchi M., Kawano H., Sato S., Ishizaki J., Shimoda H., Yamashita K., Matsuoka H., Shimoda K.
International Journal of Hematology 108 ( 4 ) 411 - 415 2018年10月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：International Journal of Hematology
© 2018, The Japanese Society of Hematology. A new entity, namely early/prefibrotic primary myelofibrosis (PMF), was introduced as a subtype of PMF in the 2016 revised World Health Organization (WHO) criteria for myeloproliferative neoplasms (MPN). It was diagnosed based on histopathological features of bone marrow (BM) biopsy specimens together with clinical parameters [leukocytosis, anemia, elevated lactate dehydrogenase (LDH) values, and splenomegaly]. The aim of this study was to evaluate the prevalence of early/prefibrotic PMF in patients who were previously diagnosed with ET, and to compare clinical features at diagnosis and outcomes between early/prefibrotic PMF and essential thrombocythemia (ET) patients. BM biopsy samples obtained at the time of ET diagnosis were available in 42 patients. Sample reevaluation according to the 2016 revised WHO criteria revealed that early/prefibrotic PMF accounted for 14% of patients who were previously diagnosed with ET, which was comparable to the rates in previous reports. Compared to patients with ET, patients with early/prefibrotic PMF had higher LDH values and higher frequencies of splenomegaly. Overall, myelofibrosis-free and acute myeloid leukemia-free survivals were comparable between the 2 groups. Accurate diagnosis is required to clarify the clinical features of Japanese ET patients.
-
Outcome of allogeneic hematopoietic cell transplantation in patients with adult T-cell leukemia
Kamiunten A., Sekine M., Kameda T., Akizuki K., Tahira Y., Shide K., Shimoda H., Kato K., Hidaka T., Kubuki Y., Shimoda K.
Hematological Oncology 36 ( 4 ) 651 - 655 2018年10月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Hematological Oncology
© 2018 The Authors Hematological Oncology Published by John Wiley & Sons Ltd Adult T-cell leukemia/lymphoma (ATL) is an aggressive peripheral T-cell neoplasm, and the outcome of patients with ATL after chemotherapy is poor. Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is a curative treatment modality for ATL, and four factors, namely, age > 50 years, male recipient, lack of complete remission at transplantation, and transplantation of cord blood, were previously shown to be associated with poor survival. We retrospectively analyzed the outcome of 21 patients with ATL who had undergone allo-HSCT at our hospital during a 3-year period. Of 21 patients, all had at least one of the above risk factors, and 18 had two or more. With a median follow-up of 19.7 months for living patients, the 1- and 2-year overall survival (OS) rates after transplantation were 34% and 27%, respectively. All relapse/progression events occurred within 1 year after allo-HSCT, and the cumulative incidence of relapse/progression at 1 year after allo-HSCT was 46.9%. The 100-day and 1-year nonrelapse mortality (NRM) rates were 19% and 42%, respectively. No significant difference in OS was observed between myeloablative and reduced-intensity conditioning regimens. The 3-year OS (27%) of ATL patients who received allo-HSCT and who had at least one adverse factor was somewhat poorer than the 3-year OS of 33% identified in a nationwide study of allo-HSCT in ATL patients in Japan. The high relapse/progression and NRM rates are major problems to be solved to achieve better outcome.
DOI： 10.1002/hon.2549
-
The clinical impact of human T-lymphotrophic virus type 1 (HTLV-1) infection on the development of adult T-cell leukemia-lymphoma (ATL) or HTLV-1-associated myelopathy (HAM) / atypical HAM after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and renal transplantation. 査読あり
Noriaki Kawano, Shuro Yoshida, Sayaka Kawano, Takuro Kuriyama, Yoshihiro Tahara, Atsushi Toyofuku, Tatsuya Manabe, Atsushi Doi, Soushi Terasaka, Kiyoshi Yamashita, Yuji Ueda, Hidenobu Ochiai, Kousuke Marutsuka, Yoshihisa Yamano, Kazuya Shimoda, Ikuo Kikuchi:
Journal of clinical and experimental hematopathology. 58 ( 3 ) 107 - 121 2018年9月
-
Kamiunten A., Shide K., Kameda T., Sekine M., Kubuki Y., Ito M., Toyama T., Kawano N., Marutsuka K., Maeda K., Takeuchi M., Kawano H., Sato S., Ishizaki J., Akizuki K., Tahira Y., Shimoda H., Hidaka T., Yamashita K., Matsuoka H., Shimoda K.
International Journal of Hematology 107 ( 6 ) 681 - 688 2018年6月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：International Journal of Hematology
© 2018, The Japanese Society of Hematology. Polycythemia vera (PV) and essential thrombocythemia (ET) are associated with life-threatening thrombohemorrhagic events, and disease progression and development of non-hematological malignancies also reduce long-term survival. We retrospectively surveyed thrombohemorrhagic events and overall survival (OS) in 62 PV and 117 ET patients. The cumulative incidences of thrombohemorrhagic events in PV and ET patients were 11.3 and 10.3%, and the incidence rates were 2.42 and 1.85 per 100 person-years. The combined incidence rates of disease progression and development of non-hematological malignancies in PV and ET patients were 1.73 and 1.69 per 100 person-years. The incidence rates of thrombohemorrhagic events in our Japanese PV/ET patients were lower than those reported by most Western studies, but were comparable to those in the largest prospective observational study in ET patients. The combined incidence rates of disease progression and development of non-hematological malignancies were similar between Japanese and Western PV/ET patients. In ET patients, the conventional risk stratification model based on the presence of advanced age or history of thrombosis was useful to predict thrombosis risk, and both the conventional model and the International Prognostic Score of thrombosis in ET based on the above 2 risk factors plus increased leukocyte count could predict poor survival.
-
Effect of ruxolitinib therapy on the quality of life of Japanese patients with myelofibrosis. 査読あり
Oritani K, Ohishi K, Okamoto S, Kirito K, Komatsu N, Tauchi T, Handa H, Saito S, Takenaka K, Shimoda K, Okada H, Amagasaki T, Wakase S, Shimozuma K, Akashi K
Current medical research and opinion. 34 ( 3 ) 531 - 537 2018年3月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. 査読あり
Kataoka K, Iwanaga M, Yasunaga JI, Nagata Y, Kitanaka A, Kameda T, Yoshimitsu M, Shiraishi Y, Sato-Otsubo A, Sanada M, Chiba K, Tanaka H, Ochi Y, Aoki K, Suzuki H, Shiozawa Y, Yoshizato T, Sato Y, Yoshida K, Nosaka K, Hishizawa M, Itonaga H, Imaizumi Y, Munakata W, Shide K, Kubuki Y, Hidaka T, Nakamaki T, Ishiyama K, Miyawaki S, Ishii R, Nureki O, Tobinai K, Miyazaki Y, Takaori-Kondo A, Shibata T, Miyano S, Ishitsuka K, Utsunomiya A, Shimoda K, Matsuoka M, Watanabe T, Ogawa S
Blood. 131 ( 2 ) 215 - 225 2018年1月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Sequential Organ Failure Assessment (SOFA) score as a prognostic factor for disseminated intravascular coagulation patients with infectious disease treated with recombinant human soluble thrombomodulin (rhTM) in clinical practice 査読あり
Noriaki Kawano, Akira Tasaki, Sayaka Kawano, Shuro Yoshida, Yoshihiro Tahara, Takuro Kuriyama, Kiyoshi Yamashita, Hidenobu Ochiai, Kazuya Shimoda, Ikuo Kikuchi
Japanese Journal of Transfusion and Cell Therapy. 63 ( 6 ) 763 - 779 2017年12月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. 査読あり
Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J
Journal of clinical oncology. 35 ( 34 ) 3844 - 3850 2017年12月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study). 査読あり
Kobayashi T, Nannya Y, Ichikawa M, Oritani K, Kanakura Y, Tomita A, Kiyoi H, Kobune M, Kato J, Kawabata H, Shindo M, Torimoto Y, Yonemura Y, Hanaoka N, Nakakuma H, Hasegawa D, Manabe A, Fujishima N, Fujii N, Tanimoto M, Morita Y, Matsuda A, Fujieda A, Katayama N, Ohashi H, Nagai H, Terada Y, Hino M, Sato K, Obara N, Chiba S, Usuki K, Ohta M, Imataki O, Uemura M, Takaku T, Komatsu N, Kitanaka A, Shimoda K, Watanabe K, Tohyama K, Takaori-Kondo A, Harigae H, Arai S, Miyazaki Y, Ozawa K, Kurokawa M, for National Research Group on Idiopathic Bone Marrow Failure Syndromes.
American Journal of hematology. 92 ( 12 ) 1324 - 1332 2017年9月
-
Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2V617F-induced Murine Myeloproliferative Neoplasm. 査読あり
Yamaji T, Shide K, Kameda T, Sekine M, Kamiunten A, Hidaka T, Kubuki Y, Shimoda H, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, Shimoda K
Anticancer research. 37 ( 7 ) 3841 - 3847 2017年7月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Prediction of Sustained Virological Response to Telaprevir/Simeprevir-Based Triple Therapy in Patients with Genotype 1 Hepatitis C Virus Using Super-Early Viral Response within 2 Weeks. 査読あり
Ozono Y, Takaishi Y, Tsuchimochi M, Nakamura K, Abe H, Miike T, Kusumoto K, Iwakiri H, Sueta M, Tahara Y, Yamamoto S, Hasuike S, Nagata K, Shimoda K
Journal of Liver. 6 ( 6 ) 1 - 6 2017年7月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms. 査読あり
Ueda K, Ikeda K, Ikezoe T, Harada-Shirado K, Ogawa K, Hashimoto Y, Sano T, Ohkawara H, Kimura S, Shichishima-Nakamura A, Nakamura Y, Shikama Y, Mori T, Mason PJ, Bessler M, Morishita S, Komatsu N, Shide K, Shimoda K, Koide S, Aoyama K, Oshima M, Iwama A, Takeishi Y
Blood advances. 1 ( 15 ) 1001 - 1015 2017年6月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib. 査読あり
Shide K., Kameda T., Yamaji T., Sekine M., Inada N., Kamiunten A., Akizuki K., Nakamura K., Hidaka T., Kubuki Y., Shimoda H., Kitanaka A., Honda A., Sawaguchi A., Abe H., Miike T., Iwakiri H., Tahara Y., Sueta M., Hasuike S., Yamamoto S., Nagata K., Shimoda K.
Leukemia. 31 ( 5 ) 1136 - 1144 2017年5月
-
Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice. 査読あり
Sekine M, Kubuki Y, Kameda T, Takeuchi M, Toyama T, Kawano N, Maeda K, Sato S, Ishizaki J, Kawano H, Kamiunten A, Akizuki K, Tahira Y, Shimoda H, Shide K, Hidaka T, Kitanaka A, Yamashita K, Matsuoka H, Shimoda K
European journal of haematology. 98 ( 5 ) 501 - 507 2017年5月
記述言語：英語 掲載種別：研究論文（学術雑誌）
DOI： 10.1111/ejh.12863
-
Impact of TET2 Deficiency on Iron Metabolism in Erythroblasts. 査読あり
Inokura K, Fujiwara T, Saito K, Iino T, Hatta S, Okitsu Y, Fukuhara N, Onishi Y, Ishizawa K, Shimoda K, Harigae H
Experimental hematology. 49 56 - 67.e5 2017年5月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome. 査読あり
Hasegawa N, Oshima M, Sashida G, Matsui H, Koide S, Saraya A, Wang C, Muto T, Takane K, Kaneda A, Shimoda K, Nakaseko C, Yokote K, Iwama A
Leukemia. 31 ( 4 ) 861 - 871 2017年4月
記述言語：英語 掲載種別：研究論文（学術雑誌）
DOI： 10.1038/leu.2016.268